Current Value
$7.741 Year Return
Current Value
$7.741 Year Return
Yahoo
Continued Clear Visual Evidence of Almost Completely Healed Skin After 6 weeks TreatmentHigh Durability of Treatment Effect of QRX003 with Continuous Daily Dosing Patient Continues Not to Require Previously Necessary MedicationsWith Patient’s Pruritus Almost Completely Eliminated, Patient Continues to Experience Zero Nightly Sleep Disturbance No Adverse Events Reported from 6 Weeks of Whole Body Treatment with QRX003Approval Received to Initiate Whole Body Testing of a Second Pediatric Patient A
Yahoo
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic DermatitisThird Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent Protection for QRX003 for Netherton Syndrome Until 2045 ASHBURN, Va., March 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late-stage clinical, specialty pharmaceutical company focused on the development and commercialization of ther
Yahoo
By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Progressing studies of QRX003; positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX), a clinical stage, specialty pharmaceutical company that focuses on developing treatments for rare and orphan diseases, is expanding clinical activities studying lead asset QRX003 for the treatment of Netherton Syndrome (NS). Quoin has active
Yahoo
ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced recent corporate accomplishments and provided an update on its fourth quarter and full-year 2024 progress. Quoin CEO Michael Myers said, "2024 was without a doubt the most significant year in Quoin’s history as our team delivered tremendous progress in clinical, regulatory
Yahoo
ASHBURN, Va., March 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Thursday, March 13, 2025. The announcement will include an operational update highlighting key achievements from the quarter, recent acco
Yahoo
By M. Marin NASDAQ:QNRX READ THE FULL QNRX RESEARCH REPORT Positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical stage, specialty pharmaceutical company that focuses on developing treatments for rare and orphan diseases, initially in the dermatology space. The company is advancing clinical studies to evaluate lead asset QRX003 for the treatment of Netherton Syndrome
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KRRO | 34.69% | $135.97M | -71.75% | 0.00% |
SPWH | 32.14% | $74.28M | -43.44% | 0.00% |
VSEC | 25.92% | $2.71B | +73.40% | 0.31% |
PSQH | 24.42% | $89.26M | -49.87% | 0.00% |
LPTX | 24.28% | $17.07M | -84.96% | 0.00% |
SNCY | 23.60% | $644.35M | +9.89% | 0.00% |
LAKE | 23.59% | $169.87M | +2.35% | 0.65% |
SMC | 23.24% | $360.62M | -12.63% | 0.00% |
XNCR | 23.07% | $583.60M | -63.49% | 0.00% |
OCUL | 22.98% | $1.14B | +14.35% | 0.00% |
KBR | 22.76% | $7.24B | -15.23% | 1.10% |
UAL | 22.69% | $25.00B | +39.72% | 0.00% |
AUTL | 22.01% | $343.32M | -68.30% | 0.00% |
AAL | 21.58% | $7.76B | -20.49% | 0.00% |
MSGE | 21.35% | $1.81B | +2.83% | 0.00% |
FLR | 21.32% | $6.34B | +0.71% | 0.00% |
CGNT | 21.19% | $704.45M | +28.14% | 0.00% |
RDW | 20.77% | $996.69M | +165.50% | 0.00% |
REXR | 20.66% | $8.38B | -23.26% | 4.73% |
DY | 20.53% | $5.53B | +30.25% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NVMI | <0.01% | $5.72B | +0.31% | 0.00% |
SANA | <0.01% | $385.70M | -80.00% | 0.00% |
RVTY | 0.01% | $10.66B | -16.65% | 0.31% |
HVT | 0.02% | $342.12M | -28.30% | 6.02% |
BYND | 0.02% | $188.88M | -65.69% | 0.00% |
ROOT | -0.03% | $2.18B | +119.56% | 0.00% |
MIRM | 0.04% | $2.24B | +82.95% | 0.00% |
YETI | 0.06% | $2.66B | -20.79% | 0.00% |
PAC | 0.06% | $9.83B | +16.49% | 0.00% |
CART | -0.06% | $11.50B | +32.89% | 0.00% |
PGR | 0.07% | $164.82B | +35.81% | 1.74% |
CMPR | -0.08% | $1.12B | -50.16% | 0.00% |
MSIF | 0.09% | $715.25M | +28.42% | 7.05% |
ULS | -0.09% | $14.25B | +92.08% | 0.71% |
DNOW | -0.10% | $1.62B | +9.57% | 0.00% |
CTAS | 0.11% | $88.22B | +26.41% | 1.25% |
KC | -0.12% | $3.55B | +273.03% | 0.00% |
CQP | 0.12% | $29.63B | +27.28% | 5.30% |
IRDM | 0.12% | $2.77B | -15.74% | 2.18% |
UHT | 0.13% | $544.23M | +4.38% | 7.42% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
NTZ | -17.33% | $38.55M | -34.46% | 0.00% |
AVO | -15.55% | $764.02M | -15.15% | 0.00% |
MGPI | -13.62% | $689.42M | -59.90% | 1.47% |
KR | -13.09% | $44.68B | +24.17% | 1.89% |
FIZZ | -10.01% | $4.16B | +0.40% | 0.00% |
IMKTA | -9.15% | $1.16B | -19.46% | 1.06% |
UMC | -9.04% | $19.69B | -2.85% | 5.80% |
LRN | -8.95% | $6.69B | +118.03% | 0.00% |
HIHO | -8.88% | $8.25M | -10.29% | 3.73% |
PENG | -8.78% | $1.02B | -2.92% | 0.00% |
BJ | -8.57% | $14.71B | +39.60% | 0.00% |
BMY | -8.33% | $93.23B | +3.85% | 5.32% |
VRTX | -8.15% | $111.55B | -1.42% | 0.00% |
ROL | -8.07% | $27.32B | +19.76% | 1.14% |
USNA | -7.99% | $558.88M | -38.15% | 0.00% |
PEP | -7.93% | $180.30B | -28.19% | 4.14% |
ERIE | -7.80% | $17.14B | -7.12% | 1.44% |
BTI | -7.68% | $90.76B | +31.13% | 7.29% |
STAA | -7.64% | $905.83M | -57.09% | 0.00% |
LPG | -7.63% | $1.01B | -40.86% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BSJP | 22.97% | $953.16M | 0.43% |
IZRL | 20.79% | $105.19M | 0.49% |
JETS | 20.11% | $863.19M | 0.6% |
JAAA | 19.96% | $20.90B | 0.2% |
FDT | 19.93% | $462.53M | 0.8% |
GREK | 19.22% | $211.12M | 0.57% |
NUKZ | 18.92% | $218.87M | 0.85% |
HYLB | 18.55% | $3.68B | 0.05% |
PFFV | 18.25% | $301.24M | 0.25% |
PREF | 18.23% | $1.17B | 0.55% |
ANGL | 17.99% | $2.81B | 0.25% |
FPEI | 17.94% | $1.56B | 0.85% |
BSJQ | 17.89% | $999.94M | 0.42% |
HYS | 17.80% | $1.37B | 0.56% |
VRP | 17.59% | $2.05B | 0.5% |
FLHY | 17.39% | $627.64M | 0.4% |
USHY | 17.36% | $22.28B | 0.08% |
JNK | 17.31% | $6.98B | 0.4% |
HYDB | 17.31% | $1.61B | 0.35% |
HFND | 17.22% | $27.99M | 1.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -15.17% | $361.41M | 1.43% |
TAIL | -13.83% | $140.49M | 0.59% |
BIL | -10.03% | $45.95B | 0.1356% |
VIXY | -7.78% | $109.64M | 0.85% |
BILZ | -7.51% | $876.85M | 0.14% |
FXY | -6.83% | $838.61M | 0.4% |
TFLO | -6.63% | $7.06B | 0.15% |
IVOL | -6.61% | $353.94M | 1.02% |
BOXX | -6.42% | $6.21B | 0.19% |
XBIL | -6.18% | $782.40M | 0.15% |
TBLL | -5.84% | $2.46B | 0.08% |
UNG | -5.40% | $371.83M | 1.06% |
IYK | -4.93% | $1.48B | 0.4% |
TPMN | -4.77% | $31.54M | 0.65% |
CANE | -4.66% | $10.71M | 0.29% |
JMST | -4.32% | $3.65B | 0.18% |
XLP | -3.80% | $15.53B | 0.09% |
MUST | -3.79% | $403.58M | 0.23% |
BILS | -3.18% | $3.96B | 0.1356% |
KXI | -3.14% | $822.83M | 0.41% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
AGZD | 0.02% | $127.42M | 0.23% |
GSST | 0.07% | $857.21M | 0.16% |
FTSD | -0.17% | $212.46M | 0.25% |
BSCP | 0.19% | $3.49B | 0.1% |
FEMB | 0.28% | $154.92M | 0.85% |
VTIP | -0.39% | $14.78B | 0.03% |
STIP | 0.39% | $11.88B | 0.03% |
NYF | 0.41% | $875.13M | 0.25% |
KRBN | 0.42% | $160.09M | 0.85% |
CGSM | -0.44% | $658.61M | 0.25% |
USFR | -0.45% | $18.91B | 0.15% |
ICLO | -0.46% | $305.65M | 0.19% |
FLMX | 0.63% | $47.92M | 0.19% |
TUR | -0.64% | $139.51M | 0.59% |
IGOV | -0.66% | $994.85M | 0.35% |
FTSM | -0.72% | $6.54B | 0.45% |
FLMI | -0.77% | $649.76M | 0.3% |
IBND | 0.78% | $291.26M | 0.5% |
FXB | -0.80% | $82.87M | 0.4% |
FLIA | -0.95% | $670.20M | 0.25% |